Subscribe via RSS- NEWS ARCHIVES
-
2008
2007
2006
2005
2004
Pharma & Bio Ingredients
RCC is the most common type of kidney cancer, accounting for nine out of 10 cases, and new treatment options are needed, as fewer than 10 percent of late-stage kidney cancer patients will live five years following diagnosis. According to the American Cancer Society, there will be 38,890 new cases of kidney cancer and 12,840 kidney cancer deaths in 2006.
"We are pleased with the results demonstrating improvement in progression- free survival in this study and plan to discuss the data and the submission of an application for a potential indication in renal cell cancer with the U.S. Food and Drug Administration," said Hal Barron, M.D., Genentech's senior vice president, Development and chief medical officer. "These results reinforce our belief that inhibiting angiogenesis by specifically blocking vascular endothelial growth factor could provide important clinical benefit across a broad range of tumor types."
Adverse events in this study appeared to be similar to those previously reported for interferon and for Avastin. The most common adverse events that occurred more often in the Avastin plus interferon arm included bleeding, hypertension and proteinuria. Serious adverse events occurring more often in the Avastin plus interferon arm included fatigue, pneumonia and gastrointestinal perforations.
